Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Set to Announce Quarterly Earnings on Thursday
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is scheduled to be announcing its earnings results before the market opens on Thursday, July 27th. Analysts expect the company to announce earnings of $1.25 per share for the quarter. Alexion Pharmaceuticals has set its FY17 guidance at $5.10-5.30 EPS.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.33. The firm had revenue of $870 million during the quarter, compared to the consensus estimate of $826.63 million. Alexion Pharmaceuticals had a return on equity of 11.72% and a net margin of 14.52%. The company’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period last year, the company earned $1.11 EPS. On average, analysts expect Alexion Pharmaceuticals to post $5.32 EPS for the current fiscal year and $6.58 EPS for the next fiscal year.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at 127.30 on Thursday. The company’s 50 day moving average price is $117.19 and its 200-day moving average price is $122.79. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $145.41. The firm has a market capitalization of $28.59 billion, a P/E ratio of 60.65 and a beta of 1.39.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average cost of $116.72 per share, for a total transaction of $1,167,200.00. Following the completion of the purchase, the chief executive officer now owns 38,725 shares of the company’s stock, valued at approximately $4,519,982. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bros. Advisors Lp Baker acquired 1,348,955 shares of the company’s stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. Insiders acquired 2,019,734 shares of company stock valued at $235,606,846 in the last ninety days. Insiders own 4.35% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/20/alexion-pharmaceuticals-inc-nasdaqalxn-set-to-announce-quarterly-earnings-on-thursday.html.
Several equities analysts have recently issued reports on ALXN shares. Royal Bank Of Canada reiterated an “outperform” rating and set a $177.00 price target on shares of Alexion Pharmaceuticals in a research report on Monday, March 27th. UBS AG started coverage on Alexion Pharmaceuticals in a report on Wednesday, March 29th. They issued a “buy” rating and a $138.00 target price on the stock. Instinet restated a “buy” rating and issued a $148.00 target price on shares of Alexion Pharmaceuticals in a report on Thursday, March 30th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 18th. Finally, Cowen and Company restated an “outperform” rating and issued a $180.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, April 28th. Eight analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $156.62.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.